Patent 7425545 was granted and assigned to Ionis Pharmaceuticals on September, 2008 by the United States Patent and Trademark Office.
Compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise oligonucleotides, targeted to nucleic acid encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for diagnosis and treatment of disease associated with expression of C-reactive protein are provided.